Finally, the data from D’Incecco et al. suggest that EGFR-mutant NSCLC is highly eligible for PD-1/PD-L1 immunotherapy, and PD-L1 may represent a favorable biomarker candidate for response to EGFR-TKIs. Here, EGFR is linked to non-small cell lung carcinoma.